Cargando…
Chronic myeloid leukemia patients call for quality and consistency when generics are introduced to treat their cancer
Autores principales: | Geissler, J, Sharf, G, Cugurovic, J, Padua, R, Narbutas, Š, Remic, M, Venkatesh, V |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5155028/ https://www.ncbi.nlm.nih.gov/pubmed/27484147 http://dx.doi.org/10.1038/leu.2016.220 |
Ejemplares similares
-
Health-related quality of life of patients with resistant/intolerant chronic phase chronic myeloid leukemia treated with asciminib or bosutinib in the phase 3 ASCEMBL trial
por: Réa, Delphine, et al.
Publicado: (2023) -
Who initiates price competition when generic entrants are introduced into the South Korean pharmaceutical market?
por: Son, Kyung-Bok
Publicado: (2022) -
Treatment-free remission in chronic myeloid leukemia: the patient perspective and areas of unmet needs
por: Sharf, Giora, et al.
Publicado: (2020) -
When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia
por: Laneuville, Pierre
Publicado: (2018) -
Health-Related Quality of Life in Patients with Chronic Myeloid Leukemia Treated with First- Versus Second-Generation Tyrosine Kinase Inhibitors
por: Shacham Abulafia, Adi, et al.
Publicado: (2020)